The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

AZN ASTRAZENECA PLC ORD SHS $0.25




 Page 1 of 6

| 1 | 2 | 3 | 4 | 5 | 6 | Next

Time/Date Code Headline Source Impact
07:00 19-Jun-2019 AZN Lynparza approved in Japan for 1st-line RNS +2.96% Up
07:00 19-Jun-2019 AZN Breztri Aerosphere (PT010) approved in Japan for RNS +2.96% Up
07:00 19-Jun-2019 AZN Bevespi Aerosphere approved by the Japanese RNS +2.96% Up
07:00 18-Jun-2019 AZN Lynparza approved in the EU for 1st-line RNS +3.77% Up
07:00 17-Jun-2019 AZN Calquence significantly prolonged the time patient RNS +3.65% Up
16:45 12-Jun-2019 AZN Publication of a Prospectus RNS +3.28% Up
07:00 06-Jun-2019 AZN Calquence Phase III ELEVATE-TN trial met primary RNS +3.13% Up
15:00 03-Jun-2019 AZN Total Voting Rights RNS +1.95% Up
15:00 03-Jun-2019 AZN Block listing Interim Review RNS +1.95% Up
07:00 03-Jun-2019 AZN Lynparza nearly doubled time patients lived with RNS +1.95% Up
07:00 10-May-2019 AZN Pooled analyses of the roxadustat global Phase III RNS -0.29% Down
14:00 08-May-2019 AZN Director/PDMR Shareholding RNS +1.01% Up
11:00 08-May-2019 AZN Director Declaration RNS +1.01% Up
07:00 08-May-2019 AZN Trastuzumab deruxtecan demonstrated clinically RNS +1.01% Up
07:00 07-May-2019 AZN Calquence PhIII ASCEND trial met primary endpoint RNS +1.03% Up
07:00 03-May-2019 AZN Qternmet XR approved in the US for type-2 diabetes RNS +0.92% Up
15:00 01-May-2019 AZN Total Voting Rights RNS -2.10% Down
12:00 01-May-2019 AZN Director/PDMR Shareholding RNS -2.10% Down
07:00 29-Apr-2019 AZN Lynparza receives positive EU CHMP opinion for 1st RNS -2.53% Down
17:45 26-Apr-2019 AZN Result of AGM RNS -2.80% Down

 Page 1 of 6

| 1 | 2 | 3 | 4 | 5 | 6 | Next



Price changes are calculated on the basis of the following formula: [ avg(x) - avg(y)] / avg(y) where:
x = instrument's 7 closing prices after the news has been released
y = instrument's latest 7 closing prices before the news was released, including the day of the release of the news

Please note that the news releases are only one of the multiple factors that could have had an impact on the change in the security’s price over the time period analysed by the News Analysis tool. Where data are insufficient the graph does not show any price change and the table below the graph displays a blank “ - “ next to the line indicating the RNS issue.




Company Information
Company website http://www.astrazeneca....
Company address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom
FTSE ICB sector Pharmaceuticals & Biotechnology
FTSE ICB subsector Pharmaceuticals
Company market cap, £m* 84,504.67
Admission date 13 Jan 2006
*The company market capitalization reflects the London listed element of Ordinary and Preference shares only and is approximate. Data provided by FTSE Russell.

Security Information
FTSE index FTSE 100,FTSE 350,FTSE 350 Low Yield,FTSE 350 (ex IT),FTSE All-Share,FTSE All-Share (ex IT),FTSE Eurotop 100 Index,FTSE Eurotop 300,FTSE techMARK All-Share
Market Main Market
Market identifier code (MIC) XLON
Trading service SETS
Trading segment SET1
Listing category Premium Equity Commercial Companies
Country of share register GB
ISIN GB0009895292
SEDOL 0989529
Exchange market size 300
Security market cap, £m 84,504.67
*The market capitalisation of the security reflects data from previous trading day.


ASTRAZENECA share news analysis (AZN)